Greenwich LifeSciences (GLSI) CEO adds 2,200 shares in open-market buys

Rhea-AI Filing Summary

Snehal Patel, CEO, CFO and more than 10% owner of Greenwich LifeSciences, bought a total of 2,200 shares of common stock in open-market purchases on July 28–29, 2026, at prices of $13.10 and $13.59 per share. The purchases are reported as directly owned and not under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 2,200 shares

Net Buy 2 txns

Insider Patel Snehal

Role CEO and CFO

Bought 2,200 shs ($30K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	700	$13.10	$9K
Purchase	Common Stock	1,500	$13.59	$20K

Holdings After Transaction: Common Stock — 5,611,402 shares (Direct)

Key Figures

Shares purchased on 2026-07-29: 700 shares Shares purchased on 2026-07-28: 1,500 shares Total shares purchased: 2,200 shares +1 more

4 metrics

Shares purchased on 2026-07-29 700 shares Common Stock bought at $13.10 per share

Shares purchased on 2026-07-28 1,500 shares Common Stock bought at $13.59 per share

Total shares purchased 2,200 shares Aggregate common shares bought across reported transactions

Per-share purchase prices $13.10 and $13.59 Prices for GLSI common stock bought July 28–29, 2026

Key Terms

non-derivative, open market or private transaction, acquired_disposed_code

3 terms

non-derivative financial

"Field transaction_type is listed as non-derivative for these trades"

open market or private transaction financial

"transaction_code_description states Purchase in open market or private transaction"

acquired_disposed_code financial

"acquired_disposed_code is A, indicating an acquisition of shares"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/30/2026 - 06:05 AM Accepted by SEC EDGAR 07/30/2026 - 06:05 AM Learn about SEC filing dates

FAQ

What insider buying in GLSI did Snehal Patel report?

Snehal Patel reported buying 2,200 shares of Greenwich LifeSciences common stock. The purchases were made in two open-market trades at $13.10 and $13.59 per share on July 28 and 29, 2026, and are held directly.

On what dates did GLSI’s CEO buy additional shares?

GLSI’s CEO bought shares on July 28, 2026 and July 29, 2026. He acquired 1,500 shares at $13.59 per share on July 28 and 700 shares at $13.10 per share on July 29 in open-market transactions.

How many GLSI shares did Snehal Patel purchase in each transaction?

Snehal Patel purchased 1,500 shares of GLSI common stock in one trade and 700 shares in another. Both transactions involved non-derivative common stock and were reported as directly owned after the purchases.

At what prices did GLSI’s CEO buy the common stock?

GLSI’s CEO bought common stock at $13.59 and $13.10 per share. The 1,500-share purchase was at $13.59 per share, while the 700-share purchase was at $13.10 per share, both described as open-market or private transactions.

Were GLSI insider share purchases made under a Rule 10b5-1 plan?

The reported GLSI share purchases were not made under a Rule 10b5-1 trading plan. The Rule 10b5-1 checkbox is shown as unchecked, and no footnotes indicate that these transactions were executed pursuant to any trading arrangement.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Snehal

(Last) (First) (Middle)

C/O GREENWICH LIFESCIENCES, INC.

3992 BLUEBONNET DR., BUILDING 14

(Street)

STAFFORD TEXAS 77477

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Greenwich LifeSciences, Inc. [ GLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2026		P		1,500	A	$13.59	5,610,702	D
Common Stock	07/29/2026		P		700	A	$13.1	5,611,402	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Snehal Patel	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)